|Project Title||Principal Investigator||Institution|
|Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders||MacFabe, Derrick||University of Western Ontario|
|Exploring the neuronal phenotype of autism spectrum disorders using induced pluripotent stem cells||Hallmayer, Joachim; Dolmetsch, Ricardo||Stanford University|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|Functional study of synaptic scaffold protein SHANK3 and autism mouse model||Jiang, Yong-Hui||Duke University|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Genetic models of serotonin transporter regulation linked to mental disorders||Ramamoorthy, Sammanda||Medical University of South Carolina|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Genomic resources for identifying genes regulating social behavior||Young, Larry||Emory University|
|High content screens of neuronal development for autism research||Halpain, Shelley||University of California, San Diego|
|High-resolution diffusion tensor imaging in mouse models relevant to autism||Poptani, Harish||University of Pennsylvania|
|Identification of autism genes that regulate synaptic Nrx/Nlg signaling complexes||Garner, Craig||Stanford University|
|Identifying genetic modifiers of rett syndrome in the mouse||Buchovecky, Christine||Baylor College of Medicine|
|Identifying impairments in synaptic connectivity in mouse models of ASD||Speed, Haley||University of Texas Southwestern Medical Center|
|Insight into MeCP2 function raises therapeutic possibilities for Rett syndrome||Lomvardas, Stavros||University of California, San Francisco|
|Integrated approach to the neurobiology of autism spectrum disorders||Vaccarino, Flora||Yale University|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1||Lipton, Stuart||Burnham Institute|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2||Nakanishi, Nobuki||Burnham Institute|
|Investigating the effects of chromosome 22q11.2 deletions||Karayiorgou, Maria||Columbia University|
|Investigation of the role of MET kinase in autism||Dawson, Ted||Johns Hopkins University School of Medicine|
|Methods for production of ICSI and SCNT derived macaque stem cells||Schatten, Gerald||Southwest Foundation For Biomedical Research|
|Mice lacking Shank postsynaptic scaffolds as an animal model of autism||Sheng, Morgan||Massachusetts Institute of Technology|
|Micro-RNA regulation in pluripotent stem cells||Schatten, Gerald||Southwest Foundation For Biomedical Research|
|Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila||McDonald, Thomas||Albert Einstein College of Medicine of Yeshiva University|
|Mouse genetic model of a dysregulated serotonin transporter variant associated with autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|Murine genetic models of autism||Veenstra-Vanderweele, Jeremy||Vanderbilt University|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.